With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...
Shares of Novo Nordisk NVO gained 8.5% on Friday after the company announced positive top-line data from an early to ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, ...
Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
Popular GLP-1 medications for weight loss and diabetes may have unexpected benefits for reducing risks for conditions ...
A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...